Roche provides update on astegolimab in chronic obstructive pulmonary disease
The phase III ARNASA study did not meet the primary endpoint of a statistically significant reduction in the AER at 52 weeks
The phase III ARNASA study did not meet the primary endpoint of a statistically significant reduction in the AER at 52 weeks
Longer-term follow up in the FLAURA2 Phase III trial confirms the favourable benefit-risk profile of this combination
Reblozyl is a standard of care for the first-line treatment of anemia without previous erythropoiesis stimulating agent use
This achievement underscores our unwavering commitment to upholding the highest standards of quality, safety, and regulatory compliance
Vimta Labs has reported total income of Rs. 99.31 crores during the period ended June 30, 2025
Aims to support healthcare practitioners with evidence-based cough categorization tools that enable choosing the right molecules for effective & targeted relief from cough
The company is addressing these observations comprehensively
The receipt of EIR reaffirms the company's commitment to maintaining global quality standards
Plant-based chemistries have an outsized role to play for the HPC sector by meeting demand for good, gentle, and green products
Subscribe To Our Newsletter & Stay Updated